首页> 外文期刊>Breast Cancer: Targets and Therapy >Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment
【24h】

Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment

机译:Toll样受体信号通路对乳腺肿瘤发生和治疗的贡献

获取原文
           

摘要

Abstract: Mounting evidence indicates that anomalies in the inflammatory and immune response pathways are essential to tumorigenesis. However, tumor-based innate immunity initiated by transformed breast epithelia tissues has received much less attention. This review summarizes published reports on the role of the toll-like receptor signaling pathway on breast cancer risk, disease progression, survival, and disease recurrence. Specifically, we discuss the underlying biological mechanisms that contribute to the tumorigenic and/or anti-tumorigenic properties of toll-like receptors and their associated agonists in relation to breast tumorigenesis and cancer treatment. Further, we use results from preclinical, clinical, and population-based studies as prompts for the exploration of new and more effective breast cancer therapies. As the knowledge base of innate immunity's involvement in breast cancer progression increases, current and new immune-modifying strategies will be refined to effectively treat breast cancer.
机译:摘要:越来越多的证据表明,炎症和免疫反应途径异常是肿瘤发生必不可少的。然而,由转化的乳房上皮组织引发的基于肿瘤的先天免疫受到的关注要少得多。这篇综述总结了关于toll样受体信号转导通路在乳腺癌风险,疾病进展,生存和疾病复发中的作用的公开报道。具体而言,我们讨论了潜在的生物学机制,这些机制有助于toll样受体及其相关激动剂的致癌和/或抗致瘤特性,与乳腺癌的发生和癌症治疗有关。此外,我们将临床前,临床和基于人群的研究结果作为探索新的更有效的乳腺癌治疗方法的提示。随着先天免疫参与乳腺癌进展的知识基础的增加,当前和新的免疫调节策略将得到完善,以有效治疗乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号